XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Cash flows from operating activities:    
Net loss including noncontrolling interests in subsidiaries $ (9,018) $ (9,332)
Adjustments to reconcile net loss including noncontrolling interests in subsidiaries to net cash provided by (used in) operating activities:    
Depreciation, depletion and amortization 11,973 6,789
Accretion of asset retirement obligation 254 0
Change in fair value of Series A redeemable convertible preferred stock embedded derivatives 0 (3,954)
Change in fair value of Series B warrants 0 (2,762)
Compensation expense for share-based awards 1,749 1,351
Loss (gain) on foreign currency exchange 88 (95)
Change in fair value of equity securities 31,445 (9,960)
(Gain) loss on sale of equity securities (28,861) 9,360
Unrealized loss on derivatives 3,401 0
Deferred income taxes (10,939) (617)
Changes in assets and liabilities:    
Accounts receivable 61,727 2,629
Inventories (1,368) 216
Prepaid expenses and other assets (3,949) (1,765)
Accounts payable and accrued expenses 20,529 (10,624)
Royalties and contingent legal fees payable (5,917) (120)
Deferred revenue (159) (238)
Net cash provided by (used in) operating activities 70,955 (19,122)
Cash flows from investing activities:    
Patent acquisition (9,000) 0
Purchases of equity securities (15,544) (5,843)
Sales of equity securities 57,854 15,198
Net purchases of property and equipment and additions to oil and gas properties (143,143) (137)
Net cash (used in) provided by investing activities (109,833) 9,218
Cash flows from financing activities:    
Contributions from noncontrolling interest 15,250 0
Borrowings on the Revolving credit facility 71,475 0
Dividend on Series A Redeemable Convertible Preferred Stock 0 (1,400)
Taxes paid related to net share settlement of share-based awards (1,068) (595)
Proceeds from exercise of stock options 223 206
Net cash provided by financing activities 85,880 77,322
Effect of exchange rates on cash and cash equivalents (105) (16)
Increase in cash and cash equivalents 46,897 67,402
Cash and cash equivalents, beginning 340,091 287,786
Cash and cash equivalents, ending 386,988 355,188
Supplemental schedule of cash flow information:    
Interest paid 449 1,800
Income taxes paid 384 551
Noncash investing and financing activities:    
Accrued patent costs 5,000 0
Rights Offering    
Cash flows from financing activities:    
Proceeds from Warrant Exercises $ 0 $ 79,111